Cytokinetics
CYTK
89 hedge funds and large institutions have $101M invested in Cytokinetics in 2014 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 23 reducing their positions, and 36 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 23
18% less funds holding
Funds holding: 109 → 89 (-20)
26% less call options, than puts
Call options by funds: $2.84M | Put options by funds: $3.85M
53% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 36
53% less capital invested
Capital invested by funds: $214M → $101M (-$113M)
Top Buyers
| 1 |
AWG
Alpha Wave Global
New York
|
+$10.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$7.39M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.15M |
| 4 |
D.E. Shaw & Co
New York
|
+$5.11M |
| 5 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
+$1.74M |
Top Sellers
CYTK Hedge Fund Activity: Q2 2014 in Review
89 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2014, worth a combined $101M — down 53% from $214M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CYTK and 17 opened new positions — a net loss of 19 holders — while 23 trimmed existing stakes and 38 added.
The largest buyer was Alpha Wave Global, opening a new position worth an estimated $10.9M. The largest seller was Royce & Associates, exiting entirely with an estimated $6.65M sold.
- 89 institutional investors held Cytokinetics (CYTK) as of Q2 2014, down from 109 in Q1 2014.
- Funds reported $101M of Cytokinetics stock for Q2 2014, down 53% quarter-over-quarter.
- 17 funds opened new Cytokinetics positions in Q2 2014 and 36 closed out, a net change of -19 holders.
- The largest Cytokinetics buyer in Q2 2014 was Alpha Wave Global, an estimated $10.9M added.
- The largest Cytokinetics seller in Q2 2014 was Royce & Associates, an estimated $6.65M sold.
Based on aggregated 13F filings for Q2 2014.